Chapman & Hall/CRC Biostatistics Series- Statistical Approaches in Oncology Clinical Development Current Paradigm and Methodological Advancement
Afbeeldingen
Sla de afbeeldingen overArtikel vergelijken
- Engels
- Hardcover
- 9781498772693
- 21 november 2018
- 220 pagina's
Samenvatting
Statistical Approaches in Oncology Clinical Development : Current Paradigm and Methodological Advancement presents an overview of statistical considerations in oncology clinical trials, both early and late phase of development. It illustrates how novel statistical methods can enrich the design and analysis of modern oncology trials. The authors include many relevant real life examples from the pharmaceutical industry and academia based on their first-hand experience. Along with relevant references, the book highlights current regulatory views.
The book covers all aspects of cancer clinical trial starting from early phase development. The early part of the book covers novel phase I dose escalation design, exposure response analysis, and innovative phase II design. This includes early development strategy for cancer immunotherapy trials. The contributors also emphasized the role of biomarker and modern era of precision medicine. The second part focuses on the late stage development. This includes the application of adaptive design, safety analysis, and quality of life (QoL) data analysis. The final part discusses current regulatory perspective and challenges.
Features:
- Covers a wide spectrum of topics related to real-life statistical challenges in oncology clinical trials.
- Provides a comprehensive overview of novel statistical methods to improve trial design and statistical analysis.
- Detailed case studies illustrate the real life applications.
Satrajit Roychoudhury is a Senior Director and a member of the Statistical Research and Innovation group in Pfizer Inc. Prior to joining; he was a member of Statistical Methodology and consulting group in Novartis. He has 11 years of extensive experience in working with different phases of clinical trial. His area of research includes early phase oncology trials, survival analysis, model informed drug development, and use of Bayesian methods in clinical trials. He is industry co-chair for the ASA Biopharmaceutical Section Regulatory-Industry Workshop and has provided statistical training in major conferences including the Joint Statistical Meetings, ASA Biopharmaceutical Section Regulatory-Industry Workshop, and ICSA Applied Statistics Symposium.
Soumi Lahiri has 12 years of extensive experience in working different therapeutic areas. She is the former Director of Biostatistics in Clinical Oncology, GlaxoSmithKline. She has also worked in the oncology division of Novartis Pharmaceutical Company for two years. She is an active member of the ASA Biopharmaceutical section and former chair of the membership committee.
Productspecificaties
Inhoud
- Taal
- en
- Bindwijze
- Hardcover
- Oorspronkelijke releasedatum
- 21 november 2018
- Aantal pagina's
- 220
- Illustraties
- Nee
Betrokkenen
- Hoofdredacteur
- Satrajit Roychoudhury
- Tweede Redacteur
- Soumi Lahiri
- Hoofduitgeverij
- Chapman & Hall/Crc
Overige kenmerken
- Editie
- 1
- Extra groot lettertype
- Nee
- Product breedte
- 156 mm
- Product lengte
- 234 mm
- Studieboek
- Nee
- Verpakking breedte
- 156 mm
- Verpakking hoogte
- 234 mm
- Verpakking lengte
- 234 mm
- Verpakkingsgewicht
- 498 g
EAN
- EAN
- 9781498772693
Je vindt dit artikel in
- Categorieën
- Boek, ebook of luisterboek?
- Boek
- Taal
- Engels
- Beschikbaarheid
- Leverbaar
- Studieboek of algemeen
- Studieboeken
Kies gewenste uitvoering
Prijsinformatie en bestellen
De prijs van dit product is 141 euro en 99 cent.- Prijs inclusief verzendkosten, verstuurd door bol
- Ophalen bij een bol afhaalpunt mogelijk
- 30 dagen bedenktijd en gratis retourneren
- Dag en nacht klantenservice
Rapporteer dit artikel
Je wilt melding doen van illegale inhoud over dit artikel:
- Ik wil melding doen als klant
- Ik wil melding doen als autoriteit of trusted flagger
- Ik wil melding doen als partner
- Ik wil melding doen als merkhouder
Geen klant, autoriteit, trusted flagger, merkhouder of partner? Gebruik dan onderstaande link om melding te doen.